A statutory loss the market chose to look through

CSL (ASX:CSL) delivered its worst headline result in memory recently in August 2026 — a US$2.6 billion statutory net loss — and the share price jumped roughly 17 per cent, its best single day in more than two decades. The disconnect is the story. Investors ignored a mountain of one-off write-downs and fixed instead on three things management has spent a punishing year trying to prove: that the cost-out program is running ahead of plan, that plasma volumes are recovering, and that FY27 Earnings guidance could beat a market that had all but given up. For a stock that had languished near seven-year lows, the reset year finally produced a number worth owning.

 

What just happened

For the 12 months to 30 June 2026, CSL reported Revenue of US$15.8 billion, down 1 per cent in constant currency, and underlying NPATA of US$3.1 billion, down 2 per cent. The statutory swing to a loss — from a US$3.0 billion profit in FY25 — was driven by US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs.

The impairments were concentrated in CSL Vifor (about US$4.1 billion, including US$1.7 billion of Goodwill plus write-downs on the iron drugs Ferinject and Venofer) and roughly US$1.4 billion tied to the Lengnau Manufacturing site and self-amplifying mRNA intellectual property.

Crucially, the transformation program delivered US$176 million of savings in FY26, comfortably ahead of the roughly US$100 million target set a year earlier. CSL held the Dividend at US$2.92 and announced a fresh A$1.1 billion buyback. FY27 guidance is for flat group revenue and underlying NPAT growth of about 5 per cent — against consensus nearer 2 per cent.

 

Why it matters

CSL has been treated as broken money for two years, dogged by soft immunoglobulin demand, a botched US$16 billion Vifor Acquisition and a Vaccine unit sliding with America’s collapsing flu-shot rates. This result is the first hard evidence that interim chief executive Gordon Naylor — who stepped up when Paul McKenzie retired earlier in the year — is landing the turnaround. The savings beat and the guidance upgrade matter more than the accounting loss, because they speak to earnings the company can actually keep.

 

The numbers that matter

CSL Behring, the plasma engine at 72 per cent of revenue, posted US$11.4 billion, down 1 per cent. Immunoglobulins — the swing Factor for the whole group — were flat at US$6.2 billion but grew 7 per cent in the second half, the recovery signal bulls wanted. Albumin fell 17 per cent to US$1.1 billion; haemophilia held at US$1.5 billion, with the gene therapy HEMGENIX up 25 per cent; and the hereditary angioedema Franchise rose 14 per cent to US$884 million as ANDEMBRY launched across 19 markets.

CSL Vifor grew 3 per cent to US$2.4 billion, but the internals are lopsided: dialysis products jumped 18 per cent (VELPHORO up 51 per cent on a US reimbursement tailwind that expires on 31 December 2026), while iron sales fell 16 per cent to US$915 million under generic pressure.

CSL Seqirus slipped 8 per cent to US$2.0 billion, though seasonal influenza revenue still rose 4 per cent to US$1.6 billion — CSL says it was the only global player to grow flu sales in a shrinking market.

Group gross Margin eased 50 basis points to 53.5 per cent. R&D spending fell 13 per cent to US$1.2 billion as the pipeline was pruned. Net Debt sat at US$9.3 billion, or 1.8 times EBITDA.

 

The bigger industry picture

Three structural forces frame CSL’s future. Plasma-derived therapies remain a genuine Oligopoly with high barriers and durable Demand — immunoglobulin is used across a widening set of neurological and immune conditions — but collection Economics and Yield now decide who wins. Second, the US vaccine market has turned hostile: flu vaccination rates fell about 12 per cent year-on-year (14 per cent among over-65s), a policy-driven shift that has reshaped Seqirus. Third, iron and renal care, the Vifor thesis, are being hollowed out by generics faster than CSL underwrote in 2022.

 

The bull case

The optimistic read is that FY26 was the trough. The second-half immunoglobulin rebound, plasma-collection efficiency gains and a shift to Haemonetics’ latest plasmapheresis platform all point to expanding margins in a Business that structurally compounds. The cost program is scaling toward roughly US$400 million of annualised savings and, ultimately, up to US$550 million — real Operating Leverage on a flat revenue base. With FY27 NPAT growth guided above consensus, a maintained dividend and a A$1.1 billion buyback, CSL is signalling the Balance Sheet can fund both the reset and Shareholder returns. RBC noted every segment beat on revenue and gross profit.

 

The risks

The bear case has not gone away. Immunoglobulin faces looming competition from FcRn inhibitors, and second-half strength must persist to matter. Vifor is guided to fall about 25 per cent in FY27 as VELPHORO’s reimbursement benefit lapses and generics bite — a reminder the US$4.1 billion write-down may not be the last word. Seqirus is exposed to a US immunisation backdrop no company can control. Macquarie kept CSL as its least-preferred large-cap healthcare holding, citing immunoglobulin competition. And Naylor remains interim: a permanent CEO with a mandate to reshape the portfolio could change the story again.

 

What happens next

Watch for: a permanent CEO appointment, which will set strategic direction; the FY27 first-half result expected around February 2027, the test of whether immunoglobulin momentum and cost savings are real; the northern-hemisphere flu season, which dictates Seqirus and any revival of demerger talk (management has parked the spin-off but is “preserving optionality”); the end-2026 expiry of VELPHORO’s US tailwind; and pipeline readouts including the Phase III VMX-C001 anticoagulant-reversal program.

 

Conclusion

CSL used FY26 to take its pain in one hit — kitchen-sinking Vifor, closing plasma centres and cutting 15 per cent of staff — and the market rewarded the honesty. The relief rally reflects relief, not triumph: this is a company that has stopped disappointing, not one that has reaccelerated. The plasma franchise still throws off cash, the savings are landing early and FY27 guidance gives the recovery a spine. But with Vifor shrinking, Seqirus hostage to US vaccine politics and the top Job unfilled, the comeback is a thesis to be proven quarter by quarter. The reset year is over. The rebuild has only just begun.